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A4
ECONOMIC ASPECTS OF PERIPHERAL
ARTERIAL DISEASE
The general purpose of an economic evaluation in the
field of health care is to relate the costs of a diagnostic
or therapeutic strategy to its outcomes. The two com-
ponents of the evaluation are thus a measure of effec-
tiveness and an estimate of costs . Economic evaluation
is currently both a decision tool and an evolving aca-
demic discipline.P Thus, existing guidelines reflect the
current state of the art but are subject to alterations
when new methodological tools become available.v'>
The following discussion and recommendations relate
to the interpretation and design of specialised expert
studies aimed at identifying, as accurately as possible,
the economic implications of medical procedures. It is
of course not intended that these detailed considera-
tions necessarily apply to all clinical studies.
A4.1
Perspective in Economics
The fundamental principle is that the figure chosen to
estimate the cost of given goods or a service will
depend on the viewpoint chosen; there is no "right"
figure, but rather calculations must be made consis-
tently. From the viewpoint of the patient, relevant
costs are all of the out-of-pocket expenses. This
includes, for instance, nonreimbursed medical fees
and drug costs plus non-health care costs such as
extra help in the household or alterations for an
amputee that are not covered by insurance or social
benefits. From the viewpoint of the hospital, person-
nel, equipment, supplies, capital, and overhead in the
hospital are relevant. The chosen viewpoint can affect
the results profoundly. For example, the mean costs of
treating a severe contrast reaction were found to be
$15 (Euro 14) from the perspective of the radiology
department, $910 (Euro 846) from the perspective of
the hospital, and $3,103 (Euro 2,886) for the third-
party payer. 6 Simil arly, the chairman of a medical,
surgical, or technical department is usually account-
able for personnel, equipment, maintenance, and sup-
plies in his or her own department but may not con-
sider costs borne by other departments.' The health
care system consider all medical costs but not social
costs, and the insurer will consider total payment
made to health care provlders.v' The most encompass-
ing viewpoint is society's and is recommended in cur-
rent guidelines, although it involves an exhaustive
data collection.
Recommendation 6: Perspective in economic evalu-
ation of peripheral arterial disease
It is important to collect cost and outcome data
related to the diagnosis and treatment of peripheral
arterial disease. Current guidelines recommend
that the overall societal perspective be taken to
compute the costs and effectiveness.
A4.2
General Principles of Economic Evaluation
Economic evaluation from the societal viewpoint
requires the following:
• The time horizon for the computation of costs and
benefits must be defined: that is, the time over
which the consequences of the strategy are likely to
extend.
• The case-type or the population chosen for the
assessment of costs and benefits must be defined:
the cost of a procedure will depend, for instance, on
the severity of the underlying disease or the frailty
of the patient. When economic analysis is under-
taken alongside clinical trials, costs data are usual-
ly collected on all of the patients included. An eco-
nomic evaluation performed retrospectively or
with a model requires decisions about which
patients' data will be used to derive costs and ben-
efits.
• The type of health care facility must be defined: the
costs are different from one facility to another (and
from one country to another). Factors of variation -
include the type of equipment, the quality of main-
tenance, the number of patients and the ability of
the operators. Optimally, economic assessment
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would be performed in institutions that are familiar
with the treatment of a given disease.
• The comparator for the strategy under evaluation
should be defined.
• Costs estimated from the societal viewpoint should
include both health care and non-health care costs.
Cost computations can use data collected either
prospectively or retrospectively. The advantages and
disadvantages for each design are the same as in clin-
ical studies. The distribution of cost data is usually
skewed because of outliers. Sensitivity analyses are
useful when the data used in the baseline analysis are
uncertain or likely to change in a different setting. The
sensitivity analyses explore the changes in the final
result that occur when the assumptions used in the
baseline calculations are challenged. For example, the
value for effectiveness varies within its confidence
interval.
Recommendation 7: Method of cost data collection
• Similar to clinical data, cost data ideally should
be collected prospectively.
• Sensitivity analysis should be used to consider
the uncertainty in both the effectiveness and the
cost data. An important step in a cost-effective-
ness analysis is the 'what if?' analysis, or sensi-
tivity analysis. To analyse the effect of uncertain-
ty in the estimated parameters, the uncertain
variable is varied over the range of values con-
sidered plausible and the effect on the decision
. determined.
• Prospective randomised controlled trials are con-
sidered the optimal form of assessment.
• The cost of a given strategy should be computed
on an intent-to-treat basis. In other words, the
costs of cross-over patients are attributed to
the strategy to which they were initially
randomised.
All costs and charges calculated in past studies
should be updated. The adjustment to current value
can be made either with the country's inflation rate
estimated by the consumer price index, or preferably
by the medical inflation rate, that is, the rate of
increase in the price of medical goods and services.'
Between-country comparison of costs should ideally
use purchasing power parity. When computing total
costs from a societal viewpoint, logic dictates to aggre-
gate medical (hospital and ambulatory) and social
(tangible and intangible) costs. Decision-makers, how-
ever, tend to be skeptical about this method, because
budgets are separated, sometimes very effectively, so
that money saved for ambulatory patients wiJI not
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benefit hospitals. Similarly, non-health care money
saved by a shorter length of stay, which reduces the
number of workdays lost, wiJI not be transferred to the
health care system. This illustrates one of the limits
of economic evaluation as a tool for decision
making.9,IO,1I,12
A4.3
Computation of Costs
There are many components to the "global" cost of a
diagnostic or therapeutic strategy. Ideally, decision
makers should consider all of them before making a
decision regarding which are relevant from a given
viewpoint. Costs are different from charges (or fees),
which represent the biJI (given to the patient or the
payer). Costs are, by definition, the value of resources
that were committed to one particular use, and there-
fore the opportunity to use them elsewhere is fore-
gone. Ideally, one would want to perform a full cost
accounting study, including a measure of time (ie,
time needed to perform a particular task) to estimate
the actual workload for nurses and doctors in a given
case-type. American authors commonly report cost
estimates based on charges adjusted with cost-to-
charge ratios specific for the insurer, hospital, or
department and for the fiscal year. In Europe, where
no such tool exists, authors either use the hospital
biJIing data, which is not considered an accurate esti-
mate of costs, or cost accounting data. Both costs from
within the health care system and nonhealth costs are
considered. Costs considered in an economic analysis
are tangible and intangible, positive and negative
(avoided). The cost of a strategy is thesum of all costs
related directly or indirectly to the procedure, minus
all costs averted.
Health care costs encompass the full extent of the
health care system, hospital and ambulatory. They
comprise personnel, equipment, supplies, capital, and
overheads. Both immediate costs and follow-up costs
should be included. For example, angioplasty for
femoropopliteal arterial disease may appear less
expensive than surgery when considering the initial
procedure, but it may be more expensive if failure or
major complications are included. The costs of inter-
ventional treatment for claudication were document-
ed by Hunink et al1w in the case of both angioplasty
and bypass surgery. These costs are lower than those
found for the same procedures in patients with critical
limb ischaemia. Costs for a single angioplasty proce-
dure are lower than costs for bypass, in part because
of the differing severity of the underlying arterial dis-
ease. The authors found average hospital costs of
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$6,152 ± $3,243 (Euro 5,721) and $11,582± $5,624 (Euro
10,771) for primary uncomplicated angioplasty and
bypass, respectively. A recent study documented an
average cost of 59,365 ± 4,366 (Euro 8,709) for
femoropopliteal PTA, versus 515,470 ± 7,585 (Euro
14,387) for femoropopliteal bypass." The correspon-
ding costs adjusted to a reference patient population
(51- to 70-year-old men with claudication and no pro-
cedure-related complications) were 56,500 for
femoropopliteal PTA and 512,500 for femoropopliteal
bypass. (See Costs of Treatment for Critical Limb
Ischaemia, D 5.1.2, P 5232.)
Tangible non-healtli care costs represent lost produc-
tivity (because of absence from work at the time of
treatment or during recovery, or reduced productivity
at work) by the patient and his or her family. Other
tangible non-health care costs include expenses such
as transportation, child care, home help, or alterations
in the home rendered necessary by, for example, an
amputation. The time cost is estimated by the oppor-
tunity cost of the actual time spent getting a diagnosis
and treatment. Opporiunits] costs represent the value of
outcomes that were not achieved because resources
were committed to another use. For example, the
opportunity cost of the time spent by a patient in
obtaining treatment is the amount of money that he or
she could have gained by performing other tasks.
These costs can be estimated by current market wage
rates,16.17 This may be of importance when considering
the costs to the patient of a supervised exercise pro-
gram. The value of lost productivity is derived from
the number of days of absence from work and
whether the patient resumed work after treatment.
Because many patients with PAD are older than 65
years and retired, the costs of lost productivity may be
considered negligible. There is controversy about the
inclusion in cost calculations of future unrelated
health care and non-health care costs (eg, a patient
whose life is prolonged after an intervention for CLI
may develop lung cancer and generate costs for this
disease): in the case of treatment for PAD, there is no
evidence that one treatment significantly prolongs life
compared with another, and therefore future unrelat-
ed costs would cancel out in comparisons of thera-
peutic strategies.
Intangible costs or psychological costs assess the loss
of quality of life resulting from an illness, such as anxi-
ety and pain, borne by both the patients and the rest of
society. These costs cannot be estimated by a market
price or the value of resources used in a production
process. A proposed method used to value the loss of
quality of life is willingness to pay. That is, the amount
of money that a person would be ready to pay to avoid
a certain adverse event is the cost attributed to this
event. For example, society may be willing to pay a cer-
tain amount to avoid diagnostic angiography and
replace it by magnetic resonance angiography (MRA).
Another method is to exclude these costs from the cost
computations and include them into the quality of life
computation.
Recommendation 8: Type of information to be
recorded for estimating costs.
• Maintain a record of health care resources used,
including:
- hospital days in leU/special care/wards
- procedures both in and out of the hospital
- consultations
- follow-up testing
- pharmaceuticals
- physical therapy, exercise therapy, rehabilitation
• Record the time actually spent by the patient in
obtaining health care
• Maintain a record of the duration of absence from
work, whether or not work is resumed. If work is
resumed, record at what percentage.
• Record home care resources used, out-of-pocket
expenses by patients and family
For each health care resource fixed, semi-fixed and
variable costs should ideally be estimated. Fixed costs
(sometimes referred to as overhead costs) do not vary
in the short-term when the quantity of output pro-
duced increases. These costs typically include equip-
ment, building, heating, lighting, housekeeping, and
hospital administrative and information services.
Senti-fixed costs, which increase stepwise when the out-
put increases, are often personnel costs. Variable costs
vary precisely with the level of output, and comprise
medical supplies, drugs, films, contrast media, and
maintenance (maintenance can also be a fixed cost if it
is not related to heavy use of equipment). The total
cost is the sum of fixed, semi-fixed, and variable costs.
In the long term, by definition, all costs arc variable.I"
Financial incentives may interfere with the trans-
parency of cost data. When examining the costs of
treatments performed for PAD, the role of financial
incentives should not be neglected. Given the reim-
bursement schedules used in hospitals, and the possi-
bility of billing payers differently in some countries,
the treatments of patients with peripheral vascular
disease also may depend on their insurance coverage.
For example, in a 1989 study in Long Island (New
York), Munoz et a}19 found that the cost of treating
patients in vascular surgery depended not only on the
number of comorbid conditions, but also on the payer.
Medicaid patients had an average hospital cost of
57,30-1 (Euro 6,793), whereas private insurance
patients had an average cost of 59,537 (Euro 8,869).
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The Diagnosis-Related Group (DRG) reimburse-
ment schedule also may create incentives to perform
one procedure rather than another, for example, PTA
rather than bypass, which could result in less than
optimal patient management. The incentive for US
hospitals to perform PTA was shown by Kinnison et
aJ,2° who compared the hospital charges with the
Federal reimbursement for PTA and bypass. In both
cases, the hospital charges were less than the Federal
reimbursement, but the difference was $7,655 (Euro
7,119) per case for PTA versus only $3,081 (Euro 2,865)
per case for bypass. In another setting, the inadequacy
of the DRG reimbursement system for revascularisa-
tion procedures was also noted by Gupta and Veith,"
who estimated a mean loss of over $8,000 (Euro 7,440)
per patient undergoing successful limb salvage.
A4.4
Economic Evaluation
A 4.4.1
Types of Economic Evaluations and the Trade-off
Between Costs and Effectiveness
Cost minimisation allalysis
Comparing medical strategies according to two crite-
ria, medical outcome and cost, requires some form of
aggregation. In some cases, one strategy scores better
on both outcome and cost and is therefore a dominant
strategy. In other cases, the medical outcome is known
to be equivalent across strategies, and a cost mini-
misation analysis suffices.t-
Cost-effectiveness and cost-utilityal/alysis
Comparison of medical strategies that both use differ-
ent resources and yield different outcomes requires a
different approach. Cost-effectiveness analyses com-
pare strategies, the costs of which are expressed in
monetary terms while outcomes are expressed in a
single medical unit, for example, lives saved, life
years, or quality-adjusted life years. Some authors
refer to studies expressing effectiveness as quality-
adjusted life years as cost-utility analyses.
Cost-benefit analqsis
In a cost-benefit analysis, medical outcomes are trans-
formed into monetary units, which requires express-
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ing the value of a life in terms of dollar costs. The two
foremost methods used are the human capital
approach and willingness-to-pay.t-e-e There is reluc-
tance to do this in practice, and thus, in health care
most economic evaluations are cost-effectiveness
analyses. When macro-economic decisions are consid-
ered, cost-benefit analysis is the only type of analysis
that allows comparisons of the benefits of resources
committed to different sectors of the economy.
A differentiation must be made between the term s
effectiveness, which means the outcomes of a strategy
under routine clinical conditions, and efficacy, which
means the outcomes of a strategy under the best avail-
able conditions of medical and patient manage-
ment.l,l0,11,12.2~ Most economic evaluations of medical
therapies or revascularisation procedures report data
drawn from trials or cohort studies conducted in major
tertiary-care referral centres. Thus, medical outcomes
of these studies are those obtained by highly trained
physicians, practising with standardised methods in a
technically favourable environment. Real-life out-
comes may be different, given the heterogeneity of
training, practice patterns, and availability of equip-
ment. Similar differences are likely to be found
between costs of treatment for patients included in
studies and in real life. This is attributable in part to
protocol-driven costs, but also to costs resulting from
differences in compliance on the patient's part and to
variation in practice patterns on the physician's part.
Comparing any two strategies yields one of the fol-
lowing four situations: (1) if one strategy yields
greater effectiveness at lower cost than the other strat-
egy, it is superior; (2) if it yields lower effectiveness at
higher cost, it is inferior; (3) if it yields greater effec-
tiveness at higher cost, it must be decided whether the
incremental costs are worth paying compared to the
effectiveness gained; and (4) if it yields lower effec-
tiveness at lower cost, it must be decided whether the
achieved cost savings are justified compared to the
effectiveness lost. A reference strategy, or "do-noth-
ing" strategy, should always be included, and each
strategy should be compared with its next best strate-
gy. In the case of situations (1) and (2), the decision is
straightforward. In situations (3) and (4), a trade-off
needs to be made between costs and effectiveness, and
strategies need to be compared, which is done based
on the cost-effectiveness ratio.
The ratio of incremental costs divided by incremen-
tal effectiveness, compared with the next best alterna-
tive, is the ratio of interest. A strategy is said to be infe-
rior by dominance if there is another strategy that is
more effective and less costly, and inferior by extend-
ed dominance if there is another strategy that is more
effective and has a lower incremental cost-effective-
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ness ratio. The final choice among the remaining
strategies depends on their incremental cost-effective-
ness ratios in comparison with those of other health
care programs and on society's willingness to pay.
Recommendation 9: Use of economic evaluation in
p.eripheral arterial disease
Economic evaluation can provide important infor-
mation to guide decision-makers in allocating
health care resources. It must be used in association
with other important criteria (eg, clinical and qual-
ity of life outcomes, available resources).
A4.5
Limitations of Economic Evaluation in the
Current Literature
Compared with the recommendations just stated, the
literature on the economics of PAD presents several
limitations:
• Heterogeneous population: Most cost papers report
data on a heterogeneous population. The cost
results are attributed to the case-type that was most
prevalent in the study population.
• Comorbid conditions: The description of comorbid
conditions such as CAD, chronic obstructive pul-
monary disease, renal insufficiency, and diabetes
mellitus, and of postprocedural complications
resulting from these should be part of the descrip-
tion of the population. These comorbid conditions
add extra costs and possibly result in prolonged
length of stay.
• Differences between countries: The methods of cal-
culating an economic value for a given treatment
varies between countries.
• Different perspectives in cost computation: The
viewpoints chosen for the computation of cost dif-
fer among studies and often reflect the stakes of the
authors, in relation to the financing of their health
care systems. Various financial incentives may
interfere with the transparency of cost data. Very
few articles attempt a normative computation of
costs that would include hospital, ambulatory, and
non-health care costs.
• Different periods of follow-up: The period of obser-
vation is another issue as the chronic evolution of
the disease renders follow-up necessary to assess
both the recurrent or secondary costs and the long-
term outcomes.
• Use of unsuitable end points: Intermediate end
points (duplex findings or primary patency) are not
considered suitable. End points that can be used in
outcomes assessment include: walking distance
and functional status in patients with IC, limb sal-
vage, functional status, complications in relation to
comorbid conditions, and death in CLI patients.
• Use of irrelevant unit of analysis: The relevant unit
of analysis is the patient (not the leg), which is not
always the unit used in articles.
Economicevaluations concern both diagnostic and
therapeutic strategies. The usefulness of investigating
the coronary or cerebral circulation in patients with
arterial disease of the leg has not been established in
relation to its costs. The economic evaluations of diag-
nostic strategies often result from decision-analytic
models and not from actual trials. These models pro-
vide useful information. The necessity of models for
clinical and economic outcomes stems from the
requirement, by policy-makers, agencies, and private
or public insurers, to obtain data on the results of a
given intervention on the health status of the popula-
tion and on the costs to the health care system or to
society,"
In the case of diagnostic imaging, modelling is par-
ticularly relevant, for at least two reasons: first, the
rapidly evolving technologies and the high costs asso-
ciated with their use prompt decision-makers to
request estimates of costs and outcomes before large-
scale trials have provided results; second, most out-
comes of imaging procedures are intermediate out-
comes, and would require very long follow-up and
expensive trials to be converted into health outcomes.
It would be of interest, however, to obtain validation
of the existing models with actual patient data.
The following issues concern the evaluation of the
costs of treatments:
• The cost of a procedure/of the initial admission for
a procedure should be differentiated from the total
cost of a strategy. The notion of total cost cannot be
separated from the notion of time-for how long a
follow-up have the costs been computed?-or from
the intention to treat, because the costs of a strate-
gy should be computed on an intention-to-treat
basis.
• Case types must be identified: therapeutic strate-
gies do not always identify clearly the case types
with regard to the severity, the location, and the
extension of the peripheral arterial disease, nor,
equally important when costs are concerned, with
regard to comorbid conditions. Subgroups of
patients with coronary or carotid disease, or with
underlying pulmonary disease, should be separat-
ed from healthier patients when cost estimating is
performed.
• The setting should be identified: resource use, and
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therefore costs, also will d iffer between countries,
depending on the organisation of health care deliv-
ery, financial incentives, and practice patterns.
• Different study designs (prospective, retrospective,
models, expert opinion) render cross-study com-
parisons hazardous.
• Some studies report data gathered on patients 10
years previously-it is likely that practice patterns
have changed, with regard to both surgical and
endovascular techniques and to the use of hospital
wards.
For example, the question of primary amputation
versus revascularisation for patients with CLI is diffi-
cult to answer, for a number of reasons. First, most of
the studies were retrospective, which precludes any
valid conclusion. Even when patients are adjusted for
severity, using, for example, the American Society of
Anesthesiologists (ASA) scoring system, there could
be a reasonable suspicion that primary amputation is
performed on sicker patients and that revascularisa-
tion is attempted when patients are healthier. Second,
hospital costs are not sufficient to make a comparison
for diseases that impose a major burden on society>
Third, authors comparing the costs of revascularisa-
tions with those of primary amputations report
diverging results on which is more expensive. It
appears that both are within the range of $20,000 to
$30,000 (Euro18,600-27,900) for uncomplicated
patients. When follow-up costs are included, an extra
$20,000 is added yearly for both revascularisation and
amputationP Fourth, comorbid conditions are inade-
quately reported by most authors, even though they
have a major influence on costs. Using the University
of California at Los Angeles (UCLA) data, it can be
estimated that comorbid conditions or complications
double the hospital cost." Fifth, a related issue is the
distinction between primary and secondary amputa-
tion, which is not always made clear by authors. As
mentioned, the hospital cost of a secondary amputa-
tion is usually twice the cost of a primary amputation.
Sixth, authors do not always identify clearly the stage
and type of occlusion, which constitute important cost
drivers. A meta-analysis comparing angioplasty and
surgery for patients with claudication and CLI report-
ed that the hazard rate ratios for these procedures
were 2.0 and 1.9, respectively, which means that when
a patient undergoes any type of revascularisation at
the later stage of CLI, the risks of failure and second-
ary amputation are doublcd.> Similarly, it is unclear
that an unadjusted comparison between the costs of
surgical revascularisation and balloon angioplasty is
valid, because the type of arterial disease may differ.
As found by Hunink et al,B PTA was undertaken in
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patients with less severe disease than is seen in surgi-
cal revascularisation patients (See Section D).
Costs for primary PTA are roughly 25% lower than
costs for primary bypass but increase dramatically
over bypass costs when major complications or failure
requiring re-do procedures are included. The costs for
initial PTA were $11,000 (Euro 10,230) without compli-
cation, but when a repeat or additional procedure was
required, the costs increased to 533,000 (Euro 30,690)
and increased up to $51,000 (Euro 47,430) when the
complication resulted in an amputation. Thus, it
appears that, in addition to reducing length of stay
(and using endovascular techniques), the best
approach to cost-effectiveness is the selection of
patients according to probability of success in the
revascularisation method chosen.e
A4.6
The Role of Decision Modelling and Meta-analysis
Although the randomised controlled trial (RCT) is
considered the ideal study design to evaluate efficacy
of a new treatment, performing such a trial is not
always feasible because of practical or ethical reasons.
Furthermore, the results of RCTs cannot always be
generalised, because of the restricted inclusion of
patients and the specific circumstances in which
patients are treated. In addition, the outcomes meas-
ured in RCTs usually have a limited time frame,
whereas for decision-making purposes outcomes over
a longer time frame ideally should be considered.
Finally, when evaluating diagnostic tests, randomising
patients across all possible sequences and logical com-
binations of tests would require an enormous sample
size.
Alternative methods for the evaluation of tests and
treatments are meta-analysis and decision modelling.
A meta-analysis is a systematic review and quantita-
tive analysis of the results of previous studies. A meta-
analysis involves performing a careful search for all
published studies and preferably also those unpub-
lished. Criteria need to be defined and used to deter-
mine which studies are included and which excluded.
Using analytical methods designed to adjust for dif-
ferences in case mix, one can quantitatively pool the
results and adjust for various factors that may influ-
ence the results.30.3L32 Using such techniques, the
results from various cohort seri es evaluating PTA,
stent placement, and bypass surgery for PAD have
been combined.29-13..J.l The diagnostic performance of a
test also may be systematically reviewed and sum-
marised with a meta-analysis. The data regarding
diagnostic tests are best combined in a summary
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receiver operating characteristic (SROC) curve, which
adjusts for the different positivity criteria used by var-
ious authors.v An example has been published in the
area of PAD, which metaanalyses the results of Duplex
Doppler.>
Decision analysis can be used to evaluate the trade-
offs relevant to a decision by mathematically model-
ling the risks, effectiveness, and costs of all potential
strategies.37,3S,39A theoretical model integrates all of the
available evidence and analyses which diagnostic or
therapeutic strategy optimises the management under
varying assumptions. Analyses considering therapeu-
tic options for PAD would, for example, need to con-
sider variables such as procedural mortality and mor-
bidity, patency results, and quality of life as function
of a patent vessel. 13AO Comparing treatments such as
exercise training and revascularisation involves mod-
elling the effect of the treatment in avoiding the devel-
opment of contralateral symptoms, which can require
a very complex decision model." An analysis compar-
ing diagnostic tests such as MRA and angiography
would need to include the prior probability of PAD,
data on the diagnostic performance of MRA compared
with angiography, the foregone QALY owing to miss-
ing PAD or not identifying the optimal procedure
(false negative), the negative effect on quality-adjust-
ed life years owing to incorrectly labelling someone as
having PAD or performing the wrong procedure (false
positive), and the costs of diagnosis and treatment."
Using decision models, one can determine the optimal
sequence of tests and the positivity criteria (optimal
operating points) on the receiver operating character-
istic curves of each test.
Every model has some uncertainty associated with
it. To analyse this uncertainty, one can use sensitivity
analysis. With sensitivity analysis, one evaluates the
effect of varying assumptions and determines under
what conditions and for which threshold values a par-
ticular test or treatment appears cost-effective. If many
variables are uncertain, one can perform a Monte Carlo
simulation, in which multiple runs of the model are
performed, each time drawing values for the uncertain
variables at random from their corresponding distribu-
tion . The resulting distribution of outcomes (typically
costs and effectiveness) represents the uncertainty in
the results. Using such simulation experiments, one
can simulate a clinical trial before actually performing
it, which can help focus the research question and pin-
points the information that needs to be collected dur-
ing the trial. Examples of such simulation experiments
exist in the area of PAD.~I.H
Ideally, clinical trials and modelling studies are
used to complement each other. A meta-analysis and
decision model can be used initially to summarise the
available information, explore the potential usefulness
of alternative strategies, and identify crucial variables
that need to be estimated. Subsequently, based on the
decision model, one can choose the two most relevant
strategies and compare these in a randomised con-
trolled clinical trial in which only short- and mid-term
costs and health benefits are measured. Finally, the
lifetime costs and benefits can subsequently be esti-
mated using the decision model with inputs based on
the clinical trial.
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